| 品牌 | 货号 | 包装单位 | 货期 | CAS | 产品名称 | 质量规格 | 单价(¥) | 购买数量 |
|---|---|---|---|---|---|---|---|---|
| 阿拉丁 | A126894-10mg | 10mg | 现货 | 602306-29-6 |
AZD5438,细胞周期蛋白依赖性激酶的抑制剂 AZD5438 |
Moligand™, ≥98% |
|
|
| 阿拉丁 | A126894-50mg | 50mg | 现货 | 602306-29-6 |
AZD5438,细胞周期蛋白依赖性激酶的抑制剂 AZD5438 |
Moligand™, ≥98% |
|
|
| 阿拉丁 | A126905-5mg | 5mg | 现货 | 612487-72-6 |
2-羟基-3-[5-[(吗啉-4-基)甲基]吡啶-2-基... AZD1080 |
Moligand™, ≥98% |
|
|
| 阿拉丁 | A126905-25mg | 25mg | 现货 | 612487-72-6 |
2-羟基-3-[5-[(吗啉-4-基)甲基]吡啶-2-基... AZD1080 |
Moligand™, ≥98% |
|
|
| 阿拉丁 | A126932-10mg | 10mg | 现货 | 69408-81-7 |
AS1413, 氨萘非特(Amonafide) Amonafide |
≥98% |
|
|
| 阿拉丁 | A126932-50mg | 50mg | 现货 | 69408-81-7 |
AS1413, 氨萘非特(Amonafide) Amonafide |
≥98% |
|
|
| 阿拉丁 | A126932-250mg | 250mg | 现货 | 69408-81-7 |
AS1413, 氨萘非特(Amonafide) Amonafide |
≥98% |
|
|
| 阿拉丁 | A126951-5mg | 5mg | 现货 | 722543-31-9 |
AZD1152 AZD1152 |
Moligand™, ≥98% |
|
|
| 阿拉丁 | A126951-10mg | 10mg | 现货 | 722543-31-9 |
AZD1152 AZD1152 |
Moligand™, ≥98% |
|
|
| 阿拉丁 | A126951-50mg | 50mg | 现货 | 722543-31-9 |
AZD1152 AZD1152 |
Moligand™, ≥98% |
|
|
| 阿拉丁 | A126970-25mg | 25mg | 现货 | 75747-14-7 |
17-AAG,HSP90抑制剂 17-AAG |
≥98% |
|
|
| 阿拉丁 | A126970-100mg | 100mg | 现货 | 75747-14-7 |
17-AAG,HSP90抑制剂 17-AAG |
≥98% |
|
|
| 阿拉丁 | A127001-5mg | 5mg | 现货 | 844442-38-2 |
AT7519,CDK抑制剂 AT7519 |
Moligand™, ≥99% |
|
|
| 阿拉丁 | A127001-25mg | 25mg | 现货 | 844442-38-2 |
AT7519,CDK抑制剂 AT7519 |
Moligand™, ≥99% |
|
|
| 阿拉丁 | A127001-100mg | 100mg | 期货,请咨询 | 844442-38-2 |
AT7519,CDK抑制剂 AT7519 |
Moligand™, ≥99% |
|
|
| 阿拉丁 | A127060-5mg | 5mg | 现货 | 873305-35-2 |
AIM-100,Ack1(TNK2)抑制剂 AIM-100 |
Moligand™, ≥98% |
|
|
| 阿拉丁 | A127060-10mg | 10mg | 现货 | 873305-35-2 |
AIM-100,Ack1(TNK2)抑制剂 AIM-100 |
Moligand™, ≥98% |
|
|
| 阿拉丁 | A127060-50mg | 50mg | 现货 | 873305-35-2 |
AIM-100,Ack1(TNK2)抑制剂 AIM-100 |
Moligand™, ≥98% |
|
|
| 阿拉丁 | A127060-100mg | 100mg | 现货 | 873305-35-2 |
AIM-100,Ack1(TNK2)抑制剂 AIM-100 |
Moligand™, ≥98% |
|
|
| 阿拉丁 | A127068-5mg | 5mg | 现货 | 875446-37-0 |
Anacetrapib,胆固醇脂转移蛋白阻滞剂 Anacetrapi |
Moligand™, ≥98% |
|
|